Literature DB >> 11602320

Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets.

P Parajuli1, R L Mosley, V Pisarev, J Chavez, A Ulrich, M Varney, R K Singh, J E Talmadge.   

Abstract

OBJECTIVE: Mechanisms of T-cell stimulation by Flt3 ligand (Flt3L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) remain unclear. Herein, we compared the effects of Flt3L and GM-CSF on the expansion of dendritic cells (DC) and T-cell subsets and cytokine expression.
METHODS: Naïve and effector/memory T cells were analyzed by flow cytometry (FC). CD4(+) and CD8(+) T cells and CD11c(+)CD11b(dull/-)(DC1) and CD11c(+)CD11b(+) (DC2) subsets were isolated and the frequency of IFN-gamma-, IL-12- (type 1) and IL-4-, IL-10 (type 2)-producing cells and cytokine mRNA expression evaluated.
RESULTS: Flt3L expanded both DC1 and DC2 subsets with a significantly higher percentage and number of DC1 than DC2, while GM-CSF preferentially expanded the DC2 subset. Isolated DC1 from Flt3L-injected mice had significantly higher levels of IL-12 (p40) than IL-10, while the converse occurred with DC2. The numbers of naïve and memory T cells were elevated in mice that received Flt3L or GM-CSF. However, the number of memory CD4(+) and CD8(+) T cells was significantly increased in Flt3L as compared to GM-CSF cohorts. While GM-CSF increased the frequency of both type 1 and type 2 cytokine-producing cells, Flt3L significantly augmented the frequency of type 1 T cells.
CONCLUSIONS: In contrast to GM-CSF, Flt3L preferentially induces the expansion of type 1 T cells. The mechanism of Flt3L-induced T-cell stimulation is associated with the expansion of the IL-12 (p40)-producing DC1 and memory T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602320     DOI: 10.1016/s0301-472x(01)00722-6

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  17 in total

1.  Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.

Authors:  Yohei Mineharu; Gwendalyn D King; A K M G Muhammad; Serguei Bannykh; Kurt M Kroeger; Chunyan Liu; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis.

Authors:  Balaji B Ganesh; Donald M Cheatem; Jian Rong Sheng; Chenthamarakshan Vasu; Bellur S Prabhakar
Journal:  Int Immunol       Date:  2009-01-27       Impact factor: 4.823

3.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.

Authors:  Sumia Ali; Gwendalyn D King; James F Curtin; Marianela Candolfi; Weidong Xiong; Chunyan Liu; Mariana Puntel; Queng Cheng; Jesus Prieto; Antoni Ribas; Jerzy Kupiec-Weglinski; Nico van Rooijen; Hans Lassmann; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

4.  RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels.

Authors:  Anne L Astier; Gaëlle Beriou; Thomas M Eisenhaure; Stephen M Anderton; David A Hafler; Nir Hacohen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

5.  Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

Authors:  Mohamed L Salem; Amir A Al-Khami; Sabry A El-Naggar; C Marcela Díaz-Montero; Yian Chen; David J Cole
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

6.  STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells.

Authors:  Peter A Cohen; Gary K Koski; Brian J Czerniecki; Kevin D Bunting; Xin-Yuan Fu; Zhengqi Wang; Wen-Jun Zhang; Charles S Carter; Mohamed Awad; Christopher A Distel; Hassan Nagem; Christopher C Paustian; Terrence D Johnson; John F Tisdale; Suyu Shu
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

7.  Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.

Authors:  Guillaume Cartron; Lu Zhao-Yang; Marion Baudard; Tarik Kanouni; Valérie Rouillé; Philippe Quittet; Bernard Klein; Jean-Francois Rossi
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

8.  Fms-like tyrosine kinase-3 ligand alters antigen-specific responses to infections after severe burn injury.

Authors:  Julia Bohannon; Geping Fang; Weihua Cui; Edward Sherwood; Tracy Toliver-Kinsky
Journal:  Shock       Date:  2009-10       Impact factor: 3.454

9.  Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice.

Authors:  Tracy E Toliver-Kinsky; Cheng Y Lin; David N Herndon; Edward R Sherwood
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand.

Authors:  Anna Lissina; Olivia Briceño; Georgia Afonso; Martin Larsen; Emma Gostick; David A Price; Roberto Mallone; Victor Appay
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.